Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma

NCT02584478 is registered in ClinicalTrials.gov with Advenchen Laboratories, LLC as lead sponsor.

NCT NCT02584478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02584478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma
Lead sponsor
Advenchen Laboratories, LLC
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2015
Completion date
December 31, 2024
Enrollment
294 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

cervical carcinoma, endometrial carcinoma, fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma